This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joseph, W. R. Articles by Ching, L.-M. Search for Related Content PubMed PubMed Citation Articles by Joseph, W. R. Articles by Ching, L.-M.

Stimulation of Tumors to Synthesize Tumor Necrosis Factor- in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid

A Novel Approach to Cancer Therapy¹

Auckland Cancer Society Research Centre [W. R. J., Z. C., E. S. M., B. C. B., L-M. C.] and Research Centre for Developmental Biology and Medicine [K. G. M.], University of Auckland School of Medicine, Auckland, New Zealand

The selective induction of tumor vascular collapse represents an exciting approach to cancer treatment. However, clinical evaluation of tumor necrosis factor- (TNF), an agent that accomplishes this goal, has been limited by systemic toxicity, and clinical approaches using bacterial components to induce TNF production have also been disappointing. Our laboratory has developed synthetic low molecular weight inducers of TNF, including 5,6-dimethylxanthenone-4-acetic acid (DMXAA), as an alternative strategy. DMXAA induces rapid vascular collapse in transplantable murine tumors and induces TNF synthesis in vitro in both murine and human systems. We show here that the extent of DMXAA-induced TNF synthesis is greater in tumors than that in the spleen, liver, or serum. As shown by in situ hybridization studies of the murine Colon 38 tumor, DMXAA induced tumor as well as host cells to express TNF mRNA. The distribution of cells containing TNF mRNA in tumor tissues after DMXAA administration contrasted significantly with that obtained after lipopolysaccharide (LPS) treatment, although splenic and hepatic tissues showed a similar distribution of TNF mRNA-positive cells. In the Colon 38 tumor, the action of LPS was limited to host cells in the periphery of the vessels. DMXAA treatment induced 7-fold higher peak TNF levels in tumor than in serum. In contrast, LPS treatment induced 9-fold higher TNF levels in serum than in tumor. DMXAA induced 35-fold higher TNF activity in the Colon 38 tissue than did LPS. One ovarian, one squamous, and three melanoma human tumor xenografts implanted in athymic nude mice expressed TNF mRNA of human and murine origin in response to DMXAA, confirming that DMXAA can activate both host and tumor cells. The use of low molecular weight agents to induce TNF synthesis in situ in the tumor represents a novel approach to TNF-mediated therapy of cancers.

This article has been cited by other articles:

				M. J. McKeage, P. Fong, M. Jeffery, B. C. Baguley, P. Kestell, M. Ravic, and M. B. Jameson 5,6-dimethylxanthenone-4-acetic Acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin. Cancer Res., March 15, 2006; 12(6): 1776 - 1784. [Abstract] [Full Text] [PDF]

				A. S. Jassar, E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L.-M. Ching, L. R. Kaiser, et al. Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma Cancer Res., December 15, 2005; 65(24): 11752 - 11761. [Abstract] [Full Text] [PDF]

				M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, and D. A. Bellnier Tumor Vascular Response to Photodynamic Therapy and the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid: Implications for Combination Therapy Clin. Cancer Res., June 1, 2005; 11(11): 4241 - 4250. [Abstract] [Full Text] [PDF]

				L. D. McPhail, Y.-L. Chung, B. Madhu, S. Clark, J. R. Griffiths, L. R. Kelland, and S. P. Robinson Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy Clin. Cancer Res., May 15, 2005; 11(10): 3705 - 3713. [Abstract] [Full Text] [PDF]

				D. A. Bellnier, S. O. Gollnick, S. H. Camacho, W. R. Greco, and R. T. Cheney Treatment with the Tumor Necrosis Factor-{alpha}-Inducing Drug 5,6-Dimethylxanthenone-4-Acetic Acid Enhances the Antitumor Activity of the Photodynamic Therapy of RIF-1 Mouse Tumors Cancer Res., November 15, 2003; 63(22): 7584 - 7590. [Abstract] [Full Text] [PDF]

				Z. Cao, B. C Baguley, and L.-M. Ching Interferon-inducible Protein 10 Induction and Inhibition of Angiogenesis in Vivo by the Antitumor Agent 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Cancer Res., February 1, 2001; 61(4): 1517 - 1521. [Abstract] [Full Text]

				B. G. Siim, W. T. Laux, M. D. Rutland, B. N. Palmer, and W. R. Wilson Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2'-(1,4-Diaminobutane)bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4-acetic Acid Cancer Res., August 1, 2000; 60(16): 4582 - 4588. [Abstract] [Full Text]

				L.-M. Ching, D. Goldsmith, W. R. Joseph, H. Korner, J. D. Sedgwick, and B. C. Baguley Induction of Intratumoral Tumor Necrosis Factor (TNF) Synthesis and Hemorrhagic Necrosis by 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in TNF Knockout Mice Cancer Res., July 1, 1999; 59(14): 3304 - 3307. [Abstract] [Full Text] [PDF]